Skip to main content
SpringerLink
Log in

Erdheim-Chester Disease

  • Chapter
  • First Online:
A Clinician's Pearls & Myths in Rheumatology

  • 1470 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117(10):2783–90.

    Article  CAS  PubMed  Google Scholar 

  • Das JP, Xie L, Riedl CC, et al. Cardiothoracic manifestations of Erdheim-Chester disease. Br J Radiol. 2019;92(1104):20190473.

    Article  PubMed  PubMed Central  Google Scholar 

  • Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–65.

    Article  CAS  PubMed  Google Scholar 

  • Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell Histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET Study. JAMA Oncol. 2018;4(3):384–8.

    Article  PubMed  Google Scholar 

  • Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Estrada-Veras JI, O'Brien KJ, Boyd LC, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gianfreda D, Musetti C, Nicastro M, et al. Erdheim-Chester disease as a mimic of IgG4-related disease: a case report and a review of a single-center cohort. Medicine (Baltimore). 2016;95(21):e3625.

    Article  PubMed  Google Scholar 

  • Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic Histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019;94(10):2054–71.

    Article  PubMed  Google Scholar 

  • Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929–45.

    Article  CAS  PubMed  Google Scholar 

  • Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–3.

    Article  CAS  PubMed  Google Scholar 

  • Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am. 2013;39(2):299–311.

    Article  PubMed  Google Scholar 

  • Oneal PA, Kwitkowski V, Luo L, et al. FDA approval summary: vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation. Oncologist. 2018;23(12):1520–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ozkaya N, Rosenblum MK, Durham BH, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2018;31(4):581–97.

    Article  CAS  PubMed  Google Scholar 

  • Parks NE, Goyal G, Go RS, et al. Neuroradiologic manifestations of Erdheim-Chester disease. Neurol Clin Pract. 2018;8(1):15–20.

    Article  PubMed  PubMed Central  Google Scholar 

  • Serratrice J, Granel B, De Roux C, et al. “Coated aorta”: a new sign of Erdheim-Chester disease. J Rheumatol. 2000;27(6):1550–3.

    CAS  PubMed  Google Scholar 

  • Villatoro-Villar M, Bold MS, Warrington KJ, Crowson CS, Goyal G, Shah M, Go RS, Koster MJ. Arterial involvement in Erdheim-Chester disease: A retrospective cohort study. Medicine (Baltimore). 2018;97(49):e13452. https://doi.org/10.1097/MD.0000000000013452. PMID: 30544428; PMCID: PMC6310516.

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Mayo Clinic, Rochester, MN, USA

    Matthew J. Koster

Authors
  1. Matthew J. Koster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew J. Koster .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Harvard University Massachusetts General Hospital, Boston, MA, USA

    John H. Stone

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Koster, M.J. (2023). Erdheim-Chester Disease. In: Stone, J.H. (eds) A Clinician's Pearls & Myths in Rheumatology. Springer, Cham. https://doi.org/10.1007/978-3-031-23488-0_52

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-23488-0_52

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-23487-3

  • Online ISBN: 978-3-031-23488-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation